Market News & Trends
NeuBase Therapeutics Announces Positive Preclinical Data
NeuBase Therapeutics, Inc. recently announced positive preclinical data from its pharmacokinetics studies in non-human primates (NHPs) and in vitro pharmacodynamics data in patient-derived cell lines.…
Oxford BioTherapeutics Announces Second Oncology Drug Candidate Selected to Advance Into Formal IND-Enabling Studies From Boehringer Ingelheim Collaboration
Oxford BioTherapeutics Ltd. recently announced that Boehringer Ingelheim has selected a second asset to advance into formal IND enabling studies. The asset discovery was enabled…
New Incentives & Benefits Can Boost R&D Ecosystem for New Drug Development in India
India has recently sought feedback from the top pharmaceutical companies to make regulatory changes that offer specific tax benefits for specialized research. With the government’s…
Malvern Panalytical & Concept Life Sciences Form Unique Partnership
Malvern Panalytical and Concept Life Sciences recently launched a new partnership that combines advanced instrumentation with expert analytical services for discovery and development. This collaboration…
Aravive Announces AVB-500 Improves Anti-Tumor Effects When Combined With Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib
Aravive, Inc. recently announced that AVB-500 improves anti-tumor effects when combined with the anti-angiogenic bevacizumab or the PARP inhibitor olaparib in preclinical uterine cancer models.…
Carterra Selected by La Jolla Institute of Immunology to Provide Antibody Screening & Characterization for the Coronavirus Immunotherapy Consortium (CoVIC)
Carterra Inc. and La Jolla Institute for Immunology (LJI), announced today that they will use Carterra’s proprietary LSA platform to screen hundreds of antibodies in…
Proveris Scientific Announces 25th Anniversary; Reviews Key Milestones
Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, recently announced its 25th Anniversary and…
Novavax’s NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
Novavax, Inc. recently announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its…
SPI Pharma Expands Product Portfolio to Support Development, Manufacture & Administration of Oral Dosage Forms
SPI Pharma recently announced an expansion of its line of Mannogem Mannitol products for use in multiple patient-friendly oral dosage forms to now include: Mannogem…
Positive Update on the Development of New XF‐Platform Drug Formulations
Destiny Pharma recently announced the completion of the initial phase of its project with MedPharm to develop new topical formulations of the company’s novel XF‐platform…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….